FDA Inspection
Boehringer Ingelheim Pharmaceuticals, Inc.Boehringer Ingelheim Pharmaceuticals, Inc. – FDA Inspection, Sep 11, 2025
Record Details
This FDA Inspection record concerns Boehringer Ingelheim Pharmaceuticals, Inc., with an inspection on September 11, 2025, issued by the New England District Office, covering human drugs.
- Inspection Date
- September 11, 2025
- Product Type
- Human Drugs
View Company Profile
ID · 9c62d459-d5fc-4614-8d41-987968509962
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1281125
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring: Human Drugs
FDA Citations
1- 21 CFR 312.50Ensuring compliance with plan and protocol
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Boehringer Ingelheim Pharmaceuticals, Inc.
19| Date | Classification | Office | Project area |
|---|---|---|---|
| August 25, 2026 | Not classified | New England District Office | |
| May 2, 2024 | Not classified | New England District Office | |
| September 22, 2023 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| December 12, 2019 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| December 6, 2018 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Boehringer Ingelheim Pharmaceuticals, Inc.
- FDA Inspection 1334848 - 2026-08-25
- FDA Inspection 1235545 - 2024-05-02
- FDA Inspection 1219707 - 2023-09-22
- FDA Inspection 1112627 - 2019-12-12
- FDA Inspection 1073537 - 2018-12-06
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.